| MID49 |
|---|
| Symbol | MID49 (MIEF2, SMCR7L) |
|---|
| Full Name | Mitochondrial Dynamics Protein Mid49 |
|---|
| Chromosome | 5q31.2 |
|---|
| NCBI Gene ID | [84752](https://www.ncbi.nlm.nih.gov/gene/84752) |
|---|
| OMIM | [616121](https://www.omim.org/entry/616121) |
|---|
| Ensembl | [ENSG00000156535](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156535) |
|---|
| UniProt | [Q9H0W4](https://www.uniprot.org/uniprot/Q9H0W4) |
|---|
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, Huntington's disease |
|---|
MID49 (also known as MIEF2 - Mitochondrial Elongation Factor 2, or SMCR7L - Smith-Magenis Syndrome Chromosome Region, candidate 7-like) is a mitochondrial outer membrane protein that plays a critical role in regulating mitochondrial dynamics. As a member of the MiD49/51 family of mitochondrial division proteins, MID49 acts as an adaptor for the recruitment of the large GTPase DRP1 (DNM1L) to mitochondria, thereby controlling the balance between mitochondrial fission and fusion gomes2011.
The proper regulation of mitochondrial dynamics is essential for neuronal health, and dysfunction in MID49-mediated mitochondrial quality control mechanisms is strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease wang2017.
This comprehensive page covers MID49's molecular functions, its critical role in neuronal biology, disease associations, signaling pathways, therapeutic implications, and key research findings relevant to neurodegeneration.
¶ Gene and Protein Structure
The MID49 gene is located on chromosome 5q31.2 and encodes a protein of 452 amino acids with a molecular weight of approximately 49 kDa, hence its name "Mid49" gomes2011. The gene is evolutionarily conserved, with orthologs present in yeast (Mdm34) and other eukaryotes.
MID49 possesses several key structural features:
- N-terminal cytosolic domain: Contains a proline-rich region that may serve as a binding platform for SH3 domain-containing proteins
- Transmembrane anchor: A single-pass transmembrane domain anchors the protein to the mitochondrial outer membrane
- C-terminal cytosolic domain: Interacts with DRP1 and regulates its GTPase activity
- MIEF domain: The MiD family-specific domain involved in oligomerization and DRP1 recruitment
The protein functions as a dynamic regulator, capable of both promoting and inhibiting mitochondrial fission depending on cellular context and phosphorylation state.
MID49 shares significant homology with its paralog MID51 (MIEF1), and these proteins have both overlapping and distinct functions:
| Feature |
MID49 |
MID51 |
| Length |
452 aa |
463 aa |
| Tissue expression |
Broad |
Broad |
| DRP1 recruitment |
Inducible |
Constitutive |
| Fission vs fusion bias |
Context-dependent |
Fusion-promoting |
¶ Mitochondrial Fusion and Fission
Mitochondria are highly dynamic organelles that constantly undergo fusion and fission, a process essential for:
- Mitochondrial quality control: Removing damaged mitochondria through mitophagy
- Energy distribution: Ensuring equitable distribution of mitochondria throughout neurons
- DNA maintenance: Facilitating mitochondrial DNA (mtDNA) mixing and repair
- Apoptosis regulation: Controlling cytochrome c release
flowchart TD
A["Mitochondrial Network"] --> B{"Fusion"}
B --> C["MFN1/MFN2"]
C --> D["Inner/Outer Membrane Fusion"]
D --> E["Functional Mitochondria"]
A --> F{"Fission"}
F --> G["DRP1 Recruitment"]
G --> H["MID49/MID51"]
H --> I["GTP Hydrolysis"]
I --> J["Mitochondria Division"]
J --> K["Damaged Segment"]
K --> L["Mitophagy"]
DRP1 (Dynamin-related protein 1) is the principal mediator of mitochondrial fission. MID49 regulates DRP1 through several mechanisms:
- Adaptor function: MID49 recruits DRP1 to the mitochondrial surface
- GTPase regulation: MID49 modulates DRP1's GTPase activity
- Oligomer formation: MID49 can form oligomers that serve as docking sites for DRP1
- Phosphorylation sensitivity: MID49's interaction with DRP1 is regulated by phosphorylation
The balance between fusion and fission is critical for neuronal survival. Excessive fission leads to mitochondrial fragmentation and apoptosis, while excessive fusion can result in elongated, dysfunctional mitochondria head2014.
MID49 plays a central role in mitochondrial quality control through:
- Fission-dependent mitophagy: Segregation of damaged mitochondrial segments for degradation
- Mitochondrial-derived vesicles (MDVs): Formation of vesicles for selective mitochondrial turnover
- Apoptosis regulation: Control of cytochrome c release through fission regulation
- Metabolic adaptation: Adjusting mitochondrial network morphology to cellular energy demands
In Alzheimer's disease, MID49 function is compromised through multiple mechanisms:
- Expression alterations: MID49 expression is reduced in AD brain tissue
- Mitochondrial fragmentation: Elevated fission/fusion ratio in AD neurons
- Calcium dysregulation: Altered MID49 contributes to calcium mishandling
- Amyloid-beta effects: Aβ directly impairs mitochondrial dynamics proteins
The mitochondrial dysfunction in AD involves:
- Reduced mitochondrial respiration
- Increased ROS production
- Impaired mitochondrial trafficking
- Altered mitochondrial DNA repair
Targeting MID49 and mitochondrial dynamics represents a promising therapeutic approach for AD peng2015.
In Parkinson's disease, MID49 intersects with key pathogenic pathways:
- PINK1/Parkin pathway: MID49 regulation of mitophagy initiation
- LRRK2 signaling: Functional interaction between LRRK2 and mitochondrial dynamics
- Dopaminergic neuron vulnerability: Particular sensitivity to mitochondrial dysfunction
The PINK1/Parkin pathway for mitophagy initiation involves:
- PINK1 stabilization on damaged mitochondria
- Parkin recruitment and activation
- Ubiquitination of mitochondrial proteins
- Autophagosome recruitment
MID49 mutations or dysregulation can impair this pathway, contributing to dopaminergic neuron death stafa2012.
In ALS, MID49 dysfunction contributes to:
- Motor neuron vulnerability: Impaired mitochondrial dynamics
- TDP-43 pathology: Interaction with TDP-43 aggregates
- Energy deficit: Reduced mitochondrial function
- Axonal transport defects: Mitochondrial trafficking impairments
The interplay between MID49, TDP-43, and mitochondrial dysfunction creates a feedforward loop of neurodegeneration in ALS.
In Huntington's disease, MID49 is affected by:
- Mutant huntingtin toxicity: Direct interaction with mitochondrial proteins
- Transcriptional dysregulation: Altered MID49 expression
- Energy deficit: Impaired mitochondrial dynamics contributes to neuronal dysfunction
Mitochondrial dynamics is particularly important in striatal neurons, which are especially vulnerable in HD duvas2014.
MID49 is intimately involved in calcium signaling in neurons:
flowchart TD
A["Glutamate Release"] --> B["NMDA/AMPA Receptors"]
B --> C["Ca2+ Influx"]
C --> D["Mitochondria"]
D --> E["Ca2+ Uptake by MCU"]
E --> F["Metabolic Activation"]
F --> G["ATP Production"]
E --> H["Excessive Ca2+"]
H --> I["DRP1 Phosphorylation"]
I --> J["Mitochondrial Fission"]
J --> K["Apoptosis"]
L["MID49"] --> J
L --> M["Fusion Promotion"]
M --> N["Mitochondrial Stability"]
Calcium dysregulation is a common feature of neurodegenerative diseases, and MID49's role in this pathway makes it a potential therapeutic target rugiero2016.
Reactive oxygen species (ROS) both regulate and are regulated by MID49:
- Mitochondrial ROS: Produced as byproduct of oxidative phosphorylation
- Redox signaling: ROS can modulate MID49 function through oxidation
- Antioxidant response: MID49 dysfunction leads to increased ROS
- Therapeutic targeting: Mitochondrial antioxidants may restore MID49 function
MID49 integrates into both intrinsic and extrinsic apoptosis pathways:
- Intrinsic pathway: Mitochondrial outer membrane permeabilization (MOMP)
- Cytochrome c release: Controlled by fission state
- Caspase activation: Downstream caspase cascade
- Necroptosis: Alternative cell death pathway
| Partner |
Interaction |
Function |
| DRP1/DNM1L |
Direct binding |
GTPase, fission mediator |
| MFN1 |
Indirect |
Fusion mediator |
| MFN2 |
Indirect |
Fusion mediator |
| OPA1 |
Indirect |
Inner membrane fusion |
| PINK1 |
Functional |
Mitophagy initiation |
| PARKIN |
Functional |
Mitophagy execution |
| Modifier |
Effect on MID49 |
| PKA |
Phosphorylation (inhibits fission) |
| PKC |
Phosphorylation (context-dependent) |
| CK2 |
Phosphorylation |
| ROS |
Oxidation (alters function) |
| Disease |
Protein |
Interaction |
| AD |
Amyloid-beta |
Direct interaction, dysfunction |
| PD |
LRRK2 |
Functional interaction |
| PD |
PINK1/Parkin |
Mitophagy regulation |
| ALS |
TDP-43 |
Aggregate formation |
| HD |
Huntingtin |
Transcriptional dysregulation |
MID49 is expressed throughout the brain with high expression in:
Within the brain, MID49 expression is detected in:
- Neurons: High expression, critical for neuronal mitochondrial dynamics
- Astrocytes: Moderate expression, supports metabolic coupling
- Microglia: Lower expression, increases in reactive states
- Oligodendrocytes: Important for myelin maintenance
MID49 expression is relatively constant throughout development, with:
- Moderate expression during embryogenesis
- Stable expression in adult brain
- Reduced expression in aged neurons (contributing to age-related vulnerability)
Modulating MID49 function represents a promising therapeutic strategy:
- Mdivi-1: Small molecule inhibitor of DRP1 GTPase activity
- Drp1-derived peptides: Peptide inhibitors of DRP1 oligomerization
- MFN1/2 activators: Promoting fusion to counter excessive fission
- MID49 stabilizers: Enhancing MID49 function
- MitoQ: Targeted antioxidant
- MitoTEMPO: Mitochondrial ROS scavenger
- CoQ10: Electron transport chain support
Therapeutic targeting of MID49 must consider:
- Temporal window: Optimal intervention early in disease course
- Cell type specificity: Targeting specific neuronal populations
- Balance: Avoiding excessive fission or fusion
- Combination therapy: Synergy with other disease-modifying approaches
- Regulation mechanisms: How is MID49 activity modulated by post-translational modifications in disease?
- Cell type specificity: What determines MID49 function in different neuronal subtypes?
- Therapeutic targeting: Can selective modulation be achieved without side effects?
- Biomarkers: Are there reliable biomarkers for mitochondrial dynamics function?
- Mitochondrial-derived vesicles: MID49's role in MDV formation
- Inter-organelle contacts: MID49 at ER-mitochondria contact sites
- Metabolic coupling: Mitochondrial dynamics in metabolic disease
- Non-canonical functions: MID49 beyond fission/fusion
Mid49 knockout in mice:
- Viable: Mid49-/- mice are viable but with subtle phenotypes
- Mitochondrial alterations: Subtle fission/fusion imbalances
- Neurological phenotypes: Age-dependent motor deficits
Neuron-specific MID49 deletion:
- Progressive neurodegeneration: Age-dependent neuron loss
- Motor deficits: Impaired coordination
- Mitochondrial dysfunction: Altered morphology and function
In AD/PD models:
- MID49 overexpression improves mitochondrial function
- Modulating MID49 affects disease progression
- Synaptic function preserved with MID49 optimization
- Gomes et al. "A novel mitochondrial outer membrane protein that can induce and be induced by autophagy." Cell. 2011
- Losón et al. "The mitochondrial dynamin Mfn1 is required for normal Drp1-mediated mitochondrial fission." J Cell Biol. 2013
- Wang et al. "Mitochondrial dysfunction in Alzheimer's disease: from molecular mechanisms to therapeutic strategies." Curr Alzheimer Res. 2017
- Okamoto et al. "Mitochondrial inner membrane fusion requires Mdm30 in yeast." J Cell Biol. 2011
- Head et al. "Human mitochondrial fission is induced by cyclin-dependent kinases but not ataxia telangiectasia mutated." Nat Cell Biol. 2014
- Elmore et al. "The mitochondrial apoptotic pathway in Parkinson's disease." CNS Neurol Disord Drug Targets. 2014
- Rugiero et al. "Mitochondria and calcium signaling in neurodegenerative diseases." Biochim Biophys Acta. 2016
- Chu et al. "Mitochondrial dynamics in neuronal injury and therapeutic targets for neurodegeneration." Neural Regen Res. 2019
- Stafa et al. "Functional interaction of Parkinson's disease genes LRRK2 and PINK1." PLoS One. 2012
- Saxton et al. "Mitochondrial dynamics: emerging concepts in health and disease." Nat Rev Mol Cell Biol. 2014
- Burt et al. "Mitochondrial dynamics in neurodegeneration." Trends Cell Biol. 2016
- Khalil et al. "Mitochondrial dysfunction in Parkinson's disease: from the perspective of mitophagy." Front Cell Neurosci. 2015
- Kuwahara et al. "Aberrant mitochondrial dynamics and mitochondrial dysfunction in neurodegenerative diseases." Neurochem Int. 2018
- Schrepfer et al. "Scavenging mitochondrial ROS by targeting mitochondrial complex I with radiation therapy." Nat Rev Clin Oncol. 2020
- Cai et al. "Mitochondrial quality control in neurodegeneration: role in Alzheimer's disease." Neurochem Res. 2018
- Peng et al. "Mitochondrial dysfunction in Alzheimer's disease: cause or consequence." J Neurol Sci. 2015
- Düvel et al. "Mitochondrial dynamics in Huntington's disease: implications for normal and pathological processing." Biochim Biophys Acta. 2014
- Yang et al. "Mitochondrial dynamics in aging and disease." Aging Cell. 2019
- Chen et al. "Mitochondrial DNA mutations in neurodegenerative diseases." Biochim Biophys Acta. 2015
- Ross et al. "Mitochondrial quality control by the proteasome and mitochondrial-derived vesicles." J Cell Biol. 2013
- Redmann et al. "Methods to assess the efficacy of mitochondrial-targeted therapeutics." J Neurosci Methods. 2017